There has been tremendous concern about the impending short supply of injectable methotrexate, especially for children with cancer who require large quantities. Some rheumatoid arthritis patients also use injectable methotrexate rather than oral methotrexate, so they too have been concerned. The FDA issued an update on the status of the shortage today -- and the news is good.
In addition to already announced actions, the FDA has approved a new manufacturer of preservative-free formulation of methotrexate that is expected to further bolster supply and help avert a shortage of methotrexate. The FDA expedited review of the application from APP Pharmaceuticals to help address this potential shortage. Read more about FDA actions to avert the shortage.
Related Information:
- All About Methotrexate
- More About Rheumatoid Arthritis
2/23/2012: UPDATE from FDA
No comments:
Post a Comment